1
|
Esquerré M, Holtzinger A, Wagner N, Braun M, Pichery M, Pfaender S, Sontag S, Haake K, Mirenda M, Paillasse M, Grandolfo D, Beuraud C, Richter M, Hublitz P, Bousquet J, Fabre M, Gador M, Sommermeyer D, Schneider T, Bombarde O, Esquerré C, Ysebaert L, Despas F, Austen M, Scheel A, Dangl M. Abstract 3203: EVO cells Oncology: Tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-3203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Current autologous cell therapies, with blockbuster products on the market, have been leading for a decade to unprecedented clinical successes in patients with hematological malignancies. However, these patient-derived T-cell therapies are facing many challenges. The use of GMP iPSC lines to produce immune effector cells will reduce the complexity of the manufacturing process and will provide an unlimited source of starting material. The goal of the EVOcells Oncology platform is to offer a truly allogeneic cell therapy platform to treat a broad number of cancer patients with consistent quality and scalability of the final product. Besides, the versatility of our platform to produce different immune cell types combined to customized genetic engineering strategies will bring cell therapy to the level of personalized medicine. Our “off-the-shelf” cell therapy platform has already validated two pillars: iPSC-derived NK cells (iNK) and iPSC-derived Macrophages (iMACs). Through multiple genetic engineering strategies specific to each immune cell type, we are developing a comprehensive portfolio of cell therapy products to address specific tumor escape mechanism in liquid and solid tumors. Our initial effort aimed to develop these two innate immune cell types to propose efficacious cell therapies with an increased safety profile as they have low risk of graft-versus-host disease (GvHD) or CRS (Cytokine Release Syndrome). Thanks to the expression of a broad pattern of activatory receptors, iNK cells form Immunological Synapses with tumor cells leading in turn to efficient killing with and without addition of a CAR construct. Besides, we demonstrated the possibility to combine “naked” iNK cells with marketed therapeutic monoclonal antibodies (mAb) to further improve their efficacy. At the end of the differentiation process, iMACs are showing a M0 like phenotype with high plasticity allowing the in vitro differentiation of the cells towards either a M1 or a M2 polarization in response to the appropriate stimulations. iMACs produce key macrophages cytokines and are able to kill tumor cells via ADCP (Antibody-Dependent-Cell-Phagocytosis) mechanism when combined to a therapeutic mAb. Thanks to our collaboration with clinicians at the IUCT-Oncopole (Toulouse Cancer Hospital), we were able to identify appropriate cancer indications and further demonstrate in a translational fashion that both iNK and iMACs are able to kill primary resistant tumor cells which were isolated from patient’ samples. Taken together, these results are showing the versatility and the breadth of our EVOcells Oncology platform to produce a true arsenal of cell therapies and its potential for future clinical development.
Citation Format: Michael Esquerré, Audrey Holtzinger, Nadja Wagner, Monika Braun, Mélanie Pichery, Stefanie Pfaender, Stephanie Sontag, Kathrin Haake, Michela Mirenda, Michael Paillasse, Davide Grandolfo, Chloé Beuraud, Mandy Richter, Philip Hublitz, Julien Bousquet, Marion Fabre, Mylène Gador, Daniel Sommermeyer, Tanja Schneider, Oriane Bombarde, Camille Esquerré, Loic Ysebaert, Fabien Despas, Matthias Austen, Andreas Scheel, Markus Dangl. EVOcells Oncology: Tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3203.
Collapse
|
2
|
Paillasse MR, Esquerré M, Bertrand FA, Poussereau-Pomié C, Pichery M, Visentin V, Gueguen-Dorbes G, Gaujarengues F, Barron P, Badet G, Briaux A, Ancey PB, Sibrac D, Erdociain E, Özcelik D, Meneyrol J, Martin V, Gomez-Brouchet A, Selves J, Rochaix P, Battistella M, Lebbé C, Delord JP, Dol-Gleizes F, Bono F, Blanc I, Alam A, Hunneyball I, Whittaker M, Fons P. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy. Cancer Research Communications 2022; 2:1504-1519. [PMID: 36970050 PMCID: PMC10035370 DOI: 10.1158/2767-9764.crc-22-0151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 07/13/2022] [Accepted: 11/02/2022] [Indexed: 11/30/2022]
Abstract
The receptor tyrosine kinase VEGFR-3 plays a crucial role in cancer-induced angiogenesis and lymphangiogenesis, promoting tumor development and metastasis. Here, we report the novel VEGFR-3 inhibitor EVT801 that presents a more selective and less toxic profile than two major inhibitors of VEGFRs (i.e., sorafenib and pazopanib). As monotherapy, EVT801 showed a potent antitumor effect in VEGFR-3–positive tumors, and in tumors with VEGFR-3–positive microenvironments. EVT801 suppressed VEGF-C–induced human endothelial cell proliferation in vitro and tumor (lymph)angiogenesis in different tumor mouse models. In addition to reduced tumor growth, EVT801 decreased tumor hypoxia, favored sustained tumor blood vessel homogenization (i.e., leaving fewer and overall larger vessels), and reduced important immunosuppressive cytokines (CCL4, CCL5) and myeloid-derived suppressor cells (MDSC) in circulation. Furthermore, in carcinoma mouse models, the combination of EVT801 with immune checkpoint therapy (ICT) yielded superior outcomes to either single treatment. Moreover, tumor growth inhibition was inversely correlated with levels of CCL4, CCL5, and MDSCs after treatment with EVT801, either alone or combined with ICT. Taken together, EVT801 represents a promising anti(lymph)angiogenic drug for improving ICT response rates in patients with VEGFR-3 positive tumors.
Significance:
The VEGFR-3 inhibitor EVT801 demonstrates superior selectivity and toxicity profile than other VEGFR-3 tyrosine kinase inhibitors. EVT801 showed potent antitumor effects in VEGFR-3–positive tumors, and tumors with VEGFR-3–positive microenvironments through blood vessel homogenization, and reduction of tumor hypoxia and limited immunosuppression. EVT801 increases immune checkpoint inhibitors’ antitumor effects.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Gaelle Badet
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | - Anne Briaux
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | | | - David Sibrac
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | | | | | | | | | - Anne Gomez-Brouchet
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Janik Selves
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Philippe Rochaix
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Maxime Battistella
- 5Université de Paris, Department of Pathology, AP-HP Hôpital Saint Louis, INSERM U976, Paris, France
| | - Céleste Lebbé
- 6Université de Paris, Department of Dermatology, AP-HP Hôpital Saint Louis, INSERM U976, Paris, France
| | - Jean-Pierre Delord
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | | | | | | | | | | | | | - Pierre Fons
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| |
Collapse
|
3
|
Esquerré M, Holtzinger A, Pichery M, Pfaender S, Yumlu S, Richter M, Betous D, Bombarde O, Gador M, Sailer N, Paillasse M, Ysebaert L, Despas F, Austen M, Scheel A, Dangl M. Abstract 2749: iPSC-derived natural killer cells as the front-runner program of the EVO cells Oncology platform: From inception to translational validation using patient samples. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer immunotherapy has transformed the oncology landscape and shown promising therapeutic results in the clinic but it is also clearly facing multiple limitations. So far, the focus of immunotherapies has mainly been on the modulation of T-cells. Natural killer (NK) cells offer promising perspectives for immunotherapies as they directly kill tumor cells and produce pro-inflammatory cytokines to activate and recruit T-cells and other immune cells. Thus, NK cells are considered key players in the anti-tumor immune response that can make a “cold” tumor “hot”. However, in the tumor microenvironment (TME) of cancer patients, the low numbers of NK cells present and their exhaustion due to local immunosuppression often limit tumor cell killing. The development of NK based cell therapy products can overcome these limitations, either as single therapy or in combination with biologics such as e.g. NK cell engagers or monoclonal antibodies for boosting ADCC (antibody dependent cell cytotoxicity). To overcome the main hurdle of current autologous cell therapies, the EVOcells Oncology platform aims at developing a streamlined manufacturing process for iPSC-derived immune effector cells. The goal is to develop “off-the-shelf” cell therapy products for clinical use in large patient populations. We are currently establishing a multi-asset portfolio combining multiple immune effector cell types with different genetic editing strategies that serve to optimize this approach further. iPSC-derived NK cells (iNK cells) offer an attractive option for improving both therapeutic efficacy and safety of CAR cell therapies. Our robust, feeder-free production protocol produces iNK cells that can be reliably frozen with good recovery rates. We have generated multiple genetically modified iNK cells and have validated that the genetic modifications boost iNK function. At the end of the production process, iNK cells show phenotypic properties and single cell RNA sequencing profiles comparable to blood-derived NK cells. Importantly, iNK cells are fully functional with the ability to produce key pro-inflammatory cytokines and to form lytic immunological synapses leading to efficient killing of cancer cell lines. In addition to the killing of established tumor cell lines, we also evaluated the ability of iNK cells to kill primary leukemia cells ex vivo by using blood samples from B-cell chronic lymphocytic leukemia patients. In combination with a standard of care anti-CD20 antibody, iNK cells demonstrated the ability to kill primary leukemia cells via ADCC. Taken together, these promising results obtained with iNK cells show the potential of the EVOcells Oncology platform to deliver the next generation of cell therapies in oncology paving the way to develop a portfolio of iPSC-derived immune effector cells.
Citation Format: Michael Esquerré, Audrey Holtzinger, Mélanie Pichery, Stefanie Pfaender, Saniye Yumlu, Mandy Richter, Delphine Betous, Oriane Bombarde, Mylène Gador, Nadja Sailer, Michael Paillasse, Loïc Ysebaert, Fabien Despas, Matthias Austen, Andreas Scheel, Markus Dangl. iPSC-derived natural killer cells as the front-runner program of the EVOcells Oncology platform: From inception to translational validation using patient samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2749.
Collapse
|
4
|
Casassa E, Morice-Picard F, Pichery M, Zaafouri S, Reynier M, Boralevi F, Mazereeuw-Hautier J, Jonca N. Identification et caractérisation de deux nouvelles mutations du gène SPINK5 associées à une forme atténuée du syndrome de Netherton. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Severino-Freire M, Bing Lecointe AC, Bourrat E, Pichery M, Jonca N, Chiaverini C, Mazereeuw-Hautier J. [Ichthyosis prematurity syndrome: Two new cases]. Ann Dermatol Venereol 2018; 145:603-606. [PMID: 30077338 DOI: 10.1016/j.annder.2018.02.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 10/09/2017] [Accepted: 02/14/2018] [Indexed: 11/24/2022]
Abstract
BACKGROUND Ichthyosis prematurity syndrome is a rare syndromic form of ichthyosis caused by mutations in FATP4, which plays a central role in the transport and activation of fatty acids in the epidermis and in epidermal barrier function. Despite stereotypical clinical presentation in the neonatal period, the diagnosis is not well known by clinicians. Herein we report two new cases. PATIENTS AND METHODS Case no. 1: a boy born prematurely (33weeks of gestation) to non-consanguineous French parents presented at birth with respiratory distress necessitating admission to intensive care. His skin was covered by a thick caseous vernix, especially on the scalp, eyebrows and 4 limbs. At the age of 4years, the boy's skin appeared normal. Case no. 2: a boy born prematurely to consanguineous Moroccan parents (34weeks of gestation) presented at birth with respiratory distress requiring admission to intensive care. At clinical examination, he had a whitish thick skin giving an impression of vernix caseosa, with involvement of the scalp, forehead, 4 limbs and abdomen. At the age of 2 years, his skin was normal. CONCLUSION The clinical presentation of this syndrome is typical. It is important to make the diagnosis to enable genetic counseling and planning of adequate neonatal care in the event of future pregnancies.
Collapse
Affiliation(s)
- M Severino-Freire
- Service de dermatologie, centre de référence des maladies rares de la peau, hôpital Larrey, CHU Toulouse, 24, chemin de Pouvourville, 31059 Toulouse cedex 9, France; UDEAR - UMR 1056 Inserm, université de Toulouse, hôpital Purpan, 31300 Toulouse, France.
| | - A-C Bing Lecointe
- Service de dermatologie, hôpital d'Annecy Genevois, 74370 Metz-Tessy, France
| | - E Bourrat
- Service de dermatologie, centre de référence des maladies rares de la peau, MAGEC, hôpital Saint-Louis, AP-HP, 75475 Paris, France
| | - M Pichery
- UDEAR - UMR 1056 Inserm, université de Toulouse, hôpital Purpan, 31300 Toulouse, France
| | - N Jonca
- UDEAR - UMR 1056 Inserm, université de Toulouse, hôpital Purpan, 31300 Toulouse, France
| | - C Chiaverini
- Service de dermatologie, centre de référence des maladies rares de la peau, hôpital l'Archet 2, CHU de Nice, 06200 Nice, France
| | - J Mazereeuw-Hautier
- Service de dermatologie, centre de référence des maladies rares de la peau, hôpital Larrey, CHU Toulouse, 24, chemin de Pouvourville, 31059 Toulouse cedex 9, France; UDEAR - UMR 1056 Inserm, université de Toulouse, hôpital Purpan, 31300 Toulouse, France
| |
Collapse
|
6
|
Onnis G, Bourrat E, Jonca N, Dreyfus I, Severino-Freire M, Pichery M, Fischer J, Mazereeuw-Hautier J. KLICK syndrome: an unusual phenotype. Br J Dermatol 2018; 178:1445-1446. [PMID: 29315485 DOI: 10.1111/bjd.16318] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- G Onnis
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Larrey, Paul Sabatier University, Toulouse, France
| | - E Bourrat
- Department of Dermatology, Reference Centre for Rare Skin Diseases, MAGEC Saint Louis Hospital, APHP, Paris, France
| | - N Jonca
- Epithelial Differentiation Unity and Autoimmunity Rheumatological (NEAR), University of Toulouse, Toulouse, France
| | - I Dreyfus
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Larrey, Paul Sabatier University, Toulouse, France
| | - M Severino-Freire
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Larrey, Paul Sabatier University, Toulouse, France.,Epithelial Differentiation Unity and Autoimmunity Rheumatological (NEAR), University of Toulouse, Toulouse, France
| | - M Pichery
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Hôpital Purpan, Toulouse, France
| | - J Fischer
- Institute of Human Genetics, University Medical Center Freiburg, Freiburg, Germany
| | - J Mazereeuw-Hautier
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Larrey, Paul Sabatier University, Toulouse, France.,Epithelial Differentiation Unity and Autoimmunity Rheumatological (NEAR), University of Toulouse, Toulouse, France
| |
Collapse
|
7
|
Zaafouri S, Pichery M, Huchenq A, Valentin F, Oji V, Mazereeuw-Hautier J, Serre G, Jonca N. Transcriptomic Analysis of Two Cdsn-Deficient Mice Shows Gene Signatures Biologically Relevant for Peeling Skin Disease. J Invest Dermatol 2017; 138:1431-1435. [PMID: 29277537 DOI: 10.1016/j.jid.2017.12.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 11/20/2017] [Accepted: 12/05/2017] [Indexed: 12/21/2022]
Affiliation(s)
- Sarra Zaafouri
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France
| | - Mélanie Pichery
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France
| | - Anne Huchenq
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France
| | - Frederic Valentin
- Department of Dermatology, Muenster University Hospital, Muenster, Germany
| | - Vinzenz Oji
- Department of Dermatology, Muenster University Hospital, Muenster, Germany
| | - Juliette Mazereeuw-Hautier
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France; Department of Dermatology, Reference Centre for Rare Skin Disease, Toulouse University Hospital, Toulouse, France
| | - Guy Serre
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France
| | - Nathalie Jonca
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, UMR 1056 Inserm-Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, Toulouse, France.
| |
Collapse
|
8
|
Severino Freire M, Bing Lecointe AC, Pichery M, Jonca N, Chiaverini C, Mazereeuw-Hautier J. L’ichtyose de type « syndrome ichtyose-prématurité » : un diagnostic méconnu malgré une clinique stéréotypée. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Pichery M, Huchenq A, Sandhoff R, Severino-Freire M, Zaafouri S, Opálka L, Levade T, Soldan V, Bertrand-Michel J, Lhuillier E, Serre G, Maruani A, Mazereeuw-Hautier J, Jonca N. PNPLA1 defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain PNPLA1 irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. Hum Mol Genet 2017; 26:1787-1800. [PMID: 28369476 DOI: 10.1093/hmg/ddx079] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 02/27/2017] [Indexed: 12/17/2022] Open
Abstract
Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of monogenic genodermatoses that encompasses non-syndromic disorders of keratinization. The pathophysiology of ARCI has been linked to a disturbance in epidermal lipid metabolism that impaired the stratum corneum function, leading to permeability barrier defects. Functional characterization of some genes involved in ARCI contributed to the identification of molecular actors involved in epidermal lipid synthesis, transport or processing. Recently, PNPLA1 has been identified as a gene causing ARCI. While other members of PNPLA family are key elements in lipid metabolism, the function of PNPLA1 remained unclear. We identified 5 novel PNPLA1 mutations in ARCI patients, mainly localized in the putative active enzymatic domain of PNPLA1. To investigate Pnpla1 biological role, we analysed Pnpla1-deficient mice. KO mice died soon after birth from severe epidermal permeability defects. Pnpla1-deficient skin presented an important impairment in the composition and organization of the epidermal lipids. Quantification of epidermal ceramide species highlighted a blockade in the production of ω-O-acylceramides with a concomitant accumulation of their precursors in the KO. The virtually loss of ω-O-acylceramides in the stratum corneum was linked to a defective lipid coverage of the resistant pericellular shell encapsulating corneocytes, the so-called cornified envelope, and most probably disorganized the extracellular lipid matrix. Finally, these defects in ω-O-acylceramides synthesis and cornified envelope formation were also evidenced in the stratum corneum from PNPLA1-mutated patients. Overall, our data support that PNPLA1/Pnpla1 is a key player in the formation of ω-O-acylceramide, a crucial process for the epidermal permeability barrier function.
Collapse
Affiliation(s)
- Mélanie Pichery
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France
| | - Anne Huchenq
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France
| | - Roger Sandhoff
- Lipid Pathobiochemistry Group within the Department of Cellular and Molecular Pathology, German CanCer Research Centre (DKFZ), 69120 Heidelberg, Germany.,Centre for Applied Sciences at Technical Universities (ZAFH)-Applied Biomedical Mass Spectrometry (ABIMAS), 68163 Mannheim, Germany
| | - Maella Severino-Freire
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France.,Reference Centre for Rare Skin Diseases, Larrey Hospital, Toulouse, France
| | - Sarra Zaafouri
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France
| | - Lukáš Opálka
- Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové 50005, Czech Republic
| | - Thierry Levade
- Laboratoire de Biochimie Métabolique, IFB, CHU Purpan, 31059 Toulouse, France; INSERM UMR 1037, CRCT, Université Paul Sabatier Toulouse-III, 31062 Toulouse, France
| | - Vanessa Soldan
- Plateforme de Microscopie Électronique Intégrative (METi), CBI (Centre de Biologie Intégrative) CNRS FR3743, Bat IBCG, F-31062, Toulouse, France
| | | | - Emeline Lhuillier
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France.,Plateau de Génomique GeT-Purpan, Genotoul, Hôpital Purpan, Place du Dr Baylac - TSA 40031, F-31059 Toulouse, Cedex 9, France
| | - Guy Serre
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France
| | - Annabel Maruani
- University François Rabelais Tours, 37000 Tours, CHRU Tours, Department of Dermatology, Unit of Paediatric Dermatology, 37044 Tours, France
| | - Juliette Mazereeuw-Hautier
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France.,Reference Centre for Rare Skin Diseases, Larrey Hospital, Toulouse, France
| | - Nathalie Jonca
- Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056 Inserm - Université de Toulouse, Place du Dr Baylac, Hôpital Purpan, TSA 40031, F-31059 Toulouse, Cedex 9, France
| |
Collapse
|
10
|
Roché HH, Lafouresse FF, Filleron T, Laffont R, Maisongrosse V, Pichery M, Le Guellec S, Penault-Llorca F, Lemonnier J, Lacroix-Triki M, Girard JP. Abstract P6-09-05: Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HEV are specialized blood vessels that function as portals of entry for lymphocytes into lymphoid organs and tumor tissues (Moussion and Girard, Nature 2011, 479:542-546; Girard et al, Nature Rev Immunol 2012, 12:762-773). We retrospectively considered HEV and CD8 as potential prognostic and/or predictive factors in a large randomized adjuvant trial of node positive breast cancer patients (PACS04). This trial included 3010 node positive patients randomized between anthracyclins alone or anthracyclins and docetaxel chemotherapy. Patients with HER2+ expressing tumors had a second randomization with or without trastuzumab given sequentially for one year. With 59.5 median follow-up, metastatic free interval (MFI), the first end-point, was 84.5% at 5 years for the whole population.
Methods: 1660 tumor samples (9.7% triple negative, 67.5% HR+/HER2- and 22.8% HER2+) were collected and analyzed by immunostaining on full sections for HEV (MECA-79 mAb, BD Biosciences) and CD8 (C8/144B mAb, Dako). HEV densities were determined as previously described (Martinet et al., Cancer Res 2011, 71:5678-5687). CD8+ cells and tumor-infiltrating lymphocytes (TIL) were scored according to recently published guidelines. Univariate analyses were performed using cox proportional hazard model for continuous variable. Independent analyses for the predictive evaluation of trastuzumab outcome were performed in the HER2+ subgroup.
Results: MFI and overall survival at 5 years for this series are respectively of 84.9% (TN: 77.4%, HR+/HER2-: 89%, HER2+:75.8%) and 91% not different with the total group. The table shows expression of the different markers according to the subgroup of tumors.
Marker values according to sub molecular classification TNRH+/HER2-HER2+/RH-Number1601119378Metastatic events3411990HEV/mm2(median,range)0.51 (0, 7.73)0.13 (0, 10.23)0.38 (0, 13.63)CD8score (median, range)2 (0, 3)1 (0, 3)2 (0, 3)Table 1
No difference in univariate analysis was observed in TN and HR+/HER2- subgroups in terms of relationship between marker expression and outcomes. For the HER2+ group, HEV and CD8 were correlated to better outcome (HEV: HR=0.73, p =0.011; CD8: HR=0.64; p=0.006). For HER2+ patients not receiving trastuzumab (222 pts, 55 events), CD8 was predictive of metastasis risk (HR: 0.65, p=0.032), but not HEV (HR:0.82, p=0.09). Conversely, in the trastuzumab treated group (156 pts, 35 events), HEV was significantly correlated with a lower risk of relapse (HR: 0.45, p=0.02), but CD8 was not (HR:0.63, p=0.07). TIL counts are still ongoing and will be reported at time of presentation.
Conclusions: HEV and CD8 are associated with better prognosis in the HER2+ tumor group. Interestingly, HEV presence in the tumor seems to be a significant predictive factor of trastuzumab efficacy.
Citation Format: Roché HH, Lafouresse FF, Filleron T, Laffont R, Maisongrosse V, Pichery M, Le Guellec S, Penault-Llorca F, Lemonnier J, Lacroix-Triki M, Girard J-P. Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-05.
Collapse
Affiliation(s)
- HH Roché
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - FF Lafouresse
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - T Filleron
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - R Laffont
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - V Maisongrosse
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - M Pichery
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - S Le Guellec
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - F Penault-Llorca
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - J Lemonnier
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - M Lacroix-Triki
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| | - J-P Girard
- Institut Claudius Regaud - IUCT-O, Toulouse, France; IPBS-CNRS Université, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, Paris, France
| |
Collapse
|
11
|
Zaafouri S, Huchenq-Champagne A, Pichery M, Mazereeuw-Hautier J, Serre G, Jonca N. Étude physiopathologique d’une ichtyose rare, le « Peeling Skin Disease » à l’aide d’un modèle murin inactivé pour le gène Cornéodesmosine. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Morice-Picard F, Jonca N, Pichery M, Mermin D, Leauté-Labrèze C, Taïeb A, Mazereeuw-Hautier J, Boralevi F. KLICK syndrome: recognizable phenotype and hot-spot POMP mutation. J Eur Acad Dermatol Venereol 2016; 31:e154-e156. [PMID: 27503413 DOI: 10.1111/jdv.13898] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- F Morice-Picard
- Departments of Paediatric Dermatology and Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - N Jonca
- Department of Paediatric Dermatology, Toulouse University Hospital, Toulouse, France
| | - M Pichery
- Department of Paediatric Dermatology, Toulouse University Hospital, Toulouse, France
| | - D Mermin
- Departments of Paediatric Dermatology and Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - C Leauté-Labrèze
- Departments of Paediatric Dermatology and Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - A Taïeb
- Departments of Paediatric Dermatology and Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - J Mazereeuw-Hautier
- Department of Paediatric Dermatology, Toulouse University Hospital, Toulouse, France
| | - F Boralevi
- Departments of Paediatric Dermatology and Dermatology, Bordeaux University Hospital, Bordeaux, France
| |
Collapse
|
13
|
Sedhom MAK, Pichery M, Murdoch JR, Foligné B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T, Lefrancais E, Fallon PG, Quesniaux V, Peyrin-Biroulet L, Cathomas G, Junt T, Chamaillard M, Girard JP, Ryffel B. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 2013; 62:1714-23. [PMID: 23172891 PMCID: PMC3841767 DOI: 10.1136/gutjnl-2011-301785] [Citation(s) in RCA: 167] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Inflammatory bowel diseases (IBD) have been intrinsically linked to a deregulated cytokine network, but novel therapeutic principles are urgently needed. Here we identify the interleukin (IL)-33 and its receptor ST2 as key negative regulators of wound healing and permeability in the colon of mice. DESIGN Expression of IL-33 and ST2 was determined by qRT-PCR, ELISA, immunohistochemistry and western-blot analysis. Wild-type and St2(-/-) mice were used in wound healing experiments and in two experimental models of IBD triggered by 2,4,6-trinitrobenzene sulphonic acid or dextran sodium sulphate (DSS). Neutralisation of ST2 was performed by using a specific blocking antibody. RESULTS Nuclear localisation and enhanced expression of IL-33 in myofibroblasts and enterocytes was linked to disease involvement independently of inflammation, while the expression of ST2 was primarily restricted to the colonic epithelia. In two experimental models of IBD, genetic ablation of ST2 significantly improved signs of colitis, while a sustained epithelial expression of the cyto-protective factor connexin-43 was observed in DSS-treated St2-deficient mice. Unexpectedly, absence of ST2 in non-hematopoietic cells was sufficient to protect against colitis. Consistently, specific inhibition of endogenous ST2-mediated signalling by treatment with neutralising antibody improved DSS-induced colitis. In addition, IL-33 treatment impaired epithelial barrier permeability in vitro and in vivo, whereas absence of ST2 enhanced wound healing response upon acute mechanical injury in the colon. CONCLUSIONS Our study unveiled a novel non-hematopoietic function of IL-33 in epithelial barrier function and wound healing. Therefore, blocking the IL-33/ST2 axis may represent an efficient therapy in IBD.
Collapse
Affiliation(s)
- Mamdouh A K Sedhom
- CNRS and University, UMR7355, Molecular Immunology, Orleans, France and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, RSA,The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Australia
| | - Mélanie Pichery
- CNRS, IPBS, Toulouse, France,Toulouse University, UPS, F-31077 Toulouse, France
| | - Jenna R Murdoch
- Department of Autoimmunity, Transplantation and Inflammation, Novartis Institute for Biomedical Research, Basel, Switzerland
| | - Benoit Foligné
- Institut Pasteur de Lille, Lille, France,University Lille Nord de France, Lille, France,CNRS, UMR 8204, Lille, France,Inserm, U1019, Lille, France
| | - Nathalie Ortega
- CNRS, IPBS, Toulouse, France,Toulouse University, UPS, F-31077 Toulouse, France
| | - Sylvain Normand
- Institut Pasteur de Lille, Lille, France,University Lille Nord de France, Lille, France,CNRS, UMR 8204, Lille, France,Inserm, U1019, Lille, France
| | - Kirsten Mertz
- Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland
| | - Devika Sanmugalingam
- Department of Autoimmunity, Transplantation and Inflammation, Novartis Institute for Biomedical Research, Basel, Switzerland
| | - Lea Brault
- CNRS and University, UMR7355, Molecular Immunology, Orleans, France and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, RSA
| | - Teddy Grandjean
- Institut Pasteur de Lille, Lille, France,University Lille Nord de France, Lille, France,CNRS, UMR 8204, Lille, France,Inserm, U1019, Lille, France
| | - Emma Lefrancais
- CNRS, IPBS, Toulouse, France,Toulouse University, UPS, F-31077 Toulouse, France
| | | | - Valérie Quesniaux
- CNRS and University, UMR7355, Molecular Immunology, Orleans, France and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, RSA
| | | | - Gieri Cathomas
- Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland
| | - Tobias Junt
- Department of Autoimmunity, Transplantation and Inflammation, Novartis Institute for Biomedical Research, Basel, Switzerland
| | - Mathias Chamaillard
- Institut Pasteur de Lille, Lille, France,University Lille Nord de France, Lille, France,CNRS, UMR 8204, Lille, France,Inserm, U1019, Lille, France
| | | | - Bernhard Ryffel
- CNRS and University, UMR7355, Molecular Immunology, Orleans, France and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, RSA,Artimmune SAS, Orléans, France
| |
Collapse
|
14
|
Sedhom M, Pichery M, Ortega N, Foligné B, Grandjean T, Normand S, Brault L, Lefrancais E, Fallon P, Le Bert M, Quesniaux V, Chamaillard M, Girard JP, Bernhard R. P095 Neutralizing responsiveness to Interleukin-33 abrogat1es experimental colitis through enhanced mucosal wound healing. Cytokine 2012. [DOI: 10.1016/j.cyto.2012.06.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012; 188:3488-95. [PMID: 22371395 DOI: 10.4049/jimmunol.1101977] [Citation(s) in RCA: 369] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
IL-33 (previously known as NF from high endothelial venules) is an IL-1 family cytokine that signals through the ST2 receptor and drives cytokine production in mast cells, basophils, eosinophils, invariant NKT and NK cells, Th2 lymphocytes, and type 2 innate immune cells (natural helper cells, nuocytes, and innate helper 2 cells). Little is known about endogenous IL-33; for instance, the cellular sources of IL-33 in mouse tissues have not yet been defined. In this study, we generated an Il-33-LacZ gene trap reporter strain (Il-33(Gt/Gt)) and used this novel tool to analyze expression of endogenous IL-33 in vivo. We found that the Il-33 promoter exhibits constitutive activity in mouse lymphoid organs, epithelial barrier tissues, brain, and embryos. Immunostaining with anti-IL-33 Abs, using Il-33(Gt/Gt) (Il-33-deficient) mice as control, revealed that endogenous IL-33 protein is highly expressed in mouse epithelial barrier tissues, including stratified squamous epithelia from vagina and skin, as well as cuboidal epithelium from lung, stomach, and salivary gland. Constitutive expression of IL-33 was not detected in blood vessels, revealing the existence of species-specific differences between humans and mice. Importantly, IL-33 protein was always localized in the nucleus of producing cells with no evidence for cytoplasmic localization. Finally, strong expression of the Il-33-LacZ reporter was also observed in inflamed tissues, in the liver during LPS-induced endotoxin shock, and in the lung alveoli during papain-induced allergic airway inflammation. Together, our findings support the possibility that IL-33 may function as a nuclear alarmin to alert the innate immune system after injury or infection in epithelial barrier tissues.
Collapse
Affiliation(s)
- Mélanie Pichery
- Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France
| | | | | | | | | | | | | |
Collapse
|